João Massano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5168029/publications.pdf

Version: 2024-02-01

201385 21,215 61 27 citations h-index papers

59 g-index 72 72 72 41114 docs citations times ranked citing authors all docs

133063

#	Article	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	6.3	5,298
2	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
3	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	6.3	2,123
4	Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2018, 17, 939-953.	4.9	1,573
5	Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurology, The, 2017, 16, 877-897.	4.9	1,521
6	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 88-106.	4.9	1,512
7	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	6.3	573
8	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	6.3	480
9	Oral squamous cell carcinoma: Review of prognostic and predictive factors. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2006, 102, 67-76.	1.6	477
10	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	6.3	413
11	Clinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of Management. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a008870-a008870.	2.9	288
12	A Panâ€∢scp>European Study of the <i>C9orf72</i> Repeat Associated with <scp>FTLD</scp> : Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	1.1	247
13	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2018, 14, 280-292.	0.4	246
14	A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. Nature Genetics, 2015, 47, 39-46.	9.4	245
15	The Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2017, 13, 624-633.	0.4	143
16	An updated review of Parkinson's disease genetics and clinicopathological correlations. Acta Neurologica Scandinavica, 2017, 135, 273-284.	1.0	137
17	Cognitive Impairment and Dementia in Parkinson's Disease: Clinical Features, Diagnosis, and Management. Frontiers in Neurology, 2012, 3, 88.	1.1	125
18	Suicidal ideation in a European Huntington's disease population. Journal of Affective Disorders, 2013, 151, 248-258.	2.0	74

#	Article	IF	Citations
19	Deep Brain Stimulation and Cognitive Decline in Parkinson's Disease: A Clinical Review. Frontiers in Neurology, 2012, 3, 66.	1.1	72
20	Late-onset asymmetric myoclonus: An emerging syndrome. Movement Disorders, 2011, 26, 1744-1747.	2.2	71
21	Myoclonus epilepsy and ataxia due to <scp><i>KCNC</i></scp> <i>1</i> mutation: Analysis of 20 cases and <scp>K</scp> ⁺ channel properties. Annals of Neurology, 2017, 81, 677-689.	2.8	69
22	Cognitive decline in Huntington's disease expansion gene carriers. Cortex, 2017, 95, 51-62.	1.1	50
23	The V471A Polymorphism in Autophagy-Related Gene ATG7 Modifies Age at Onset Specifically in Italian Huntington Disease Patients. PLoS ONE, 2013, 8, e68951.	1.1	49
24	Depression and Anxiety Following Deep Brain Stimulation in Parkinson's Disease: Systematic Review and Meta-Analysis. Acta Medica Portuguesa, 2014, 27, 372-382.	0.2	48
25	Physical exercise and Parkinson's disease: influence on symptoms, disease course and prevention. Reviews in the Neurosciences, 2013, 24, 139-52.	1.4	46
26	Hospital admissions 2000–2014: A retrospective analysis of 288 096 events in patients with dementia. Archives of Gerontology and Geriatrics, 2018, 77, 150-157.	1.4	36
27	Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review. Drugs, 2019, 79, 593-608.	4.9	30
28	Motion integration deficits are independent of magnocellular impairment in Parkinson's disease. Neuropsychologia, 2009, 47, 314-320.	0.7	28
29	Progranulin Peripheral Levels as a Screening Tool for the Identification of Subjects with Progranulin Mutations in a Portuguese Cohort. Neurodegenerative Diseases, 2014, 13, 214-223.	0.8	28
30	Stroke and multiple peripheral thrombotic events in an adult with varicella. European Journal of Neurology, 2008, 15, e90-1.	1.7	25
31	Successful pallidal deep brain stimulation in 15-year-old with Tourette syndrome: 2-year follow-up. Journal of Neurology, 2013, 260, 2417-2419.	1.8	20
32	Teaching Neuro <i>Image</i> : MRI in multiple system atrophy. Neurology, 2008, 71, e38.	1.5	18
33	Clinical and genetic characteristics of late-onset Huntington's disease. Parkinsonism and Related Disorders, 2019, 61, 101-105.	1.1	17
34	Long-Term Mortality Analysis in Parkinson's Disease Treated with Deep Brain Stimulation. Parkinson's Disease, 2014, 2014, 1-5.	0.6	14
35	Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study. Journal of Huntington's Disease, 2018, 7, 209-222.	0.9	14
36	Stretching the limbs? Tonic spasms in multiple sclerosis. BMJ Case Reports, 2012, 2012, bcr2012007513-bcr2012007513.	0.2	10

#	Article	IF	CITATIONS
37	Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson's Disease in a Patient with HIV Infection: Dual Clinical Benefit. Case Reports in Neurology, 2011, 3, 219-222.	0.3	9
38	Motor Complications in Parkinson's Disease: A Comprehensive Review of Emergent Management Strategies. CNS and Neurological Disorders - Drug Targets, 2013, 12, 1017-1049.	0.8	8
39	Intraoperative microelectrode recording in Parkinson's disease subthalamic deep brain stimulation: Analysis of clinical utility. Journal of Clinical Neuroscience, 2019, 69, 104-108.	0.8	8
40	Pallidal Deep Brain Stimulation in <scp>DYT</scp> 6: Significant Longâ€Term Improvement of Dystonia and Disability. Movement Disorders Clinical Practice, 2014, 1, 118-120.	0.8	7
41	Another Twist in the Tale: Intrafamilial Phenotypic Heterogeneity in <scp><i>ANO3</i></scp> â€Related Dystonia. Movement Disorders Clinical Practice, 2021, 8, 758-762.	0.8	7
42	Imaging Evidence of Nigrostriatal Degeneration in <scp>DYTâ€PRKRA</scp> . Movement Disorders Clinical Practice, 2020, 7, 472-474.	0.8	6
43	Dropped head syndrome in early-onset Parkinson disease treated with bilateral subthalamic stimulation: clinical, imaging, EMG, and biopsy findings. Neurological Sciences, 2013, 34, 593-594.	0.9	5
44	Approaching adaptive control in neurostimulation for Parkinson disease. Neurology, 2018, 90, 497-498.	1.5	5
45	Comment: New insights on cognition after deep brain stimulation in Parkinson disease. Neurology, 2015, 84, 1360-1360.	1.5	3
46	Changes in cognitive abilities after deep brain stimulation for Parkinson disease. Neurology, 2015, 84, e98-9.	1.5	3
47	Cognitive impairment and dementia—an update. Frontiers in Neurology, 2012, 3, 153.	1.1	2
48	Think Tank: Relatório Estratégico sobre Publicação CientÃfica Biomédica em Portugal. Acta Medica Portuguesa, 2014, 27, 1.	0.2	2
49	Educação Médica em Portugal. Acta Medica Portuguesa, 2016, 29, 786.	0.2	2
50	Behind the Mask: Recognizing Facial Features of Parkinson's Disease During the <scp>COVIDâ€19</scp> Pandemic. Movement Disorders, 2021, 36, 1285-1286.	2.2	2
51	Reversible parkinsonism due to a large intracranial tumour. BMJ Case Reports, 2012, 2012, bcr2012007823-bcr2012007823.	0.2	2
52	Writeclick: Neuropsychological outcome after deep brain stimulation for Parkinson disease. Neurology, 2016, 86, 1563-1564.	1.5	1
53	Parkinson's disease cluster: the wind of change. International Journal of Clinical Neurosciences and Mental Health, 2014, , 7.	0.7	1
54	Neuropsychiatric symptoms in autoimmune encephalopathies: a clinician's guide. International Journal of Clinical Neurosciences and Mental Health, 2014, , 11.	0.7	1

#	Article	IF	CITATIONS
55	Wolfram syndrome: Phenotypic heterogeneity and novel genetic variants in the WFS1 gene. EndocrinologÃa Diabetes Y Nutrición (English Ed), 2022, 69, 153-154.	0.1	1
56	Full moon fits: temporal lobe epilepsy presenting as psychosis. Acta Neuropsychiatrica, 2011, 23, 258-259.	1.0	0
57	About deep brain stimulation. Neurology, 2015, 84, e100-1.	1.5	0
58	Sudden Fixed Posturing: Beyond Functional (Psychogenic) Dystonia. European Neurology, 2017, 78, 270-271.	0.6	0
59	Parkinson's Disease: Contemporary Concepts and Clinical Management. , 2018, , 349-378.		0
60	Wolfram syndrome: Phenotypic heterogeneity and novel genetic variants in the WFS1 gene. Endocrinologia, Diabetes Y NutriciÓn, 2021, 69, 153-153.	0.1	0
61	Repetitive behaviors in Tourette Syndrome and Obsessive-Compulsive Disorder. International Journal of Clinical Neurosciences and Mental Health, 2015, , 5.	0.7	0